LRA Applauds GSK on Positive Phase 3 Study of Benlysta® in Lupus Nephritis
September 16, 2020 NEW YORK, NY. The Lupus Research Alliance welcomes positive BLISS-LN Phase 3 data published in this week’s New England Journal of Medicine, demonstrating that GSK’s drug Benlysta® (belimumab) significantly improved kidney function in adults with lupus nephritis, the most common severe complication of lupus causing inflammation and serious damage to the kidney. The […]
New Survey Shows Education and Communication Gaps in Lupus Nephritis Care
1 in 2 Lupus Nephritis Patients Don’t Know They Have Lupus New York, NY– December 7, 2020. Significant gaps in education and communication among patients and physicians pose barriers to lupus nephritis (LN) care, according to results of two companion surveys conducted by the National Kidney Foundation (NKF) and the Lupus Research Alliance (LRA). Half […]
Lupus Therapeutics Expands Collaboration with Bristol-Myers Squibb to Test Potential Treatment for Lupus
New York, NY– June 27, 2019. The Lupus Research Alliance (LRA) and its affiliate, Lupus Therapeutics, announced that it has broadened its collaboration with Bristol-Myers Squibb (BMS) to assess the investigational drug BMS-986165 as a potential new therapy for lupus nephritis (LN). This expands the existing collaboration in systemic lupus erythematosus (SLE). Lupus nephritis refers […]
LuCIN FAQ
Frequently Asked Questions About the Lupus Clinical Investigators Network (LuCIN) Clinical Research Program About LuCIN 1. What is LuCIN? Lupus Clinical Investigators Network (LuCIN) is a Lupus clinical trials network, made up of 57 of the most prestigious academic research medical centers throughout North America. Founded and sponsored by the Lupus Research Alliance, LuCIN brings […]
Pivotal LRA-Funded Research Shared at Annual Rheumatology Meeting
November 15, 2021 The Lupus Research Alliance (LRA) supports research into causes and mechanisms of lupus, and identification of targets supporting the development of new therapies or cures for lupus patients. At this year’s meeting of the American College of Rheumatology (ACR), 17 LRA-funded researchers presented their work to share discoveries with the thousands of […]
LRA Celebrates Major Research Breakthroughs in 2019
January 7, 2020 2019 was a phenomenal, breakthrough year for lupus research on both the clinical development and basic science fronts. The Lupus Research Alliance (LRA) is incredibly proud that every new discovery leading to a brand new medicine for lupus had its origin in work funded by LRA years ago. The past 12 months delivered many […]
Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network
NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3 clinical trials testing an investigational therapeutic ianalumab for systemic lupus erythematosus and lupus nephritis. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, will help Novartis Pharmaceuticals Corporation (Novartis) conduct the trials through […]
LRA-Funded Research Uncovers a Novel Pathway for Lupus Nephritis
January 28, 2022 The investigators from The Accelerated Medicines Partnership® Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Program, in collaboration with Drs. Chaim Putterman from the Albert Einstein College of Medicine and Chandra Mohan from the University of Houston, and the biotechnology company Equillium have discovered an immune pathway that plays an important role […]
LRA Announces Inaugural Awards Promoting Diversity in Lupus Research
NEW YORK, NY, June 9, 2022. The Lupus Research Alliance (LRA), the world’s leading private funder of lupus research, today announced inaugural recipients of Career Development and Postdoctoral Awards to Promote Diversity in Lupus Research. The Diversity in Lupus Research Award funding mechanisms aim to address underrepresentation of minorities in the scientific research profession. Lupus […]
Lupus Research Alliance Announces 10 Recipients of New Award in Partnership with Bristol Myers Squibb
NEW YORK, NY. July 14, 2020 — The Lupus Research Alliance (LRA) is pleased to announce the recipients of the inaugural LRA-BMS Accelerator Award*, a collaborative project with sponsoring partner Bristol Myers Squibb. The Award provides a collective total of $3,000,000 to support ten cutting-edge lupus research projects over two years that focus on […]